Influenza Vaccine News Moves Thursday's Market |
 |
 |
| By Lauran Neergaard | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Thursday, 04 June 2009 14:27 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Pharmaceutical company Hemispherx Biopharma's (Amex:HEB) shares hit a fresh 52-week high after an article in a peer-reviewed journal called its Ampligen treatment the "most promising" candidate among mucosal vaccines for preventing bird flu, and said it potentially may help with other variants of the flu. The study said mucosal vaccines are a better bet than current injection vaccines to fight a pandemic, as they may work against multiple strains. Hemispherx is waiting for approval from the FDA for Ampligen's use as a treatment for Chrinic Fatigue, but even if the approval is not given, the company has what it's CEO called "Multiple Shots on Goal," given their technology platforms for influenza prevention/control.
BiomedReports is not paid or compensated to report news and developments about publicly traded companies. Full disclosure can be read in the About Us Section Add this page to your favorite Social Bookmarking websites            |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
The spread of a new strain of influenza A H1N1 virus across 50 countries worldwide since last month has helped remind the medical community that it needs to adapt to a virus that continuously reinvents itself. That was definitely the driving force in today's markets and it will likely contintue to be a factor in coming weeks as swine flu outbreaks have overwhelmed the U.S. health-care system, a report from Bloomberg said.
The two companies which we highlighted in our (05/25/09) report 
Free Phone Trade Alerts
